Comparative Pharmacology
Head-to-head clinical analysis: APRISO versus ASACOL HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRISO versus ASACOL HD.
APRISO vs ASACOL HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene synthesis, scavenging free radicals, and activating peroxisome proliferator-activated receptor-gamma (PPAR-γ).
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
1.5 g (3 capsules) orally once daily in the morning. Each capsule contains 0.5 g mesalamine.
2 tablets (1600 mg) once daily with or without food.
None Documented
None Documented
8.6 ± 4.2 hours for mesalamine; after multiple dosing, effective half-life ~12 hours. Clinical context: allows twice-daily dosing.
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Renal (primarily as acetylated metabolite, ~80%) and fecal (~20%).
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Category C
Category C
Aminosalicylate
Aminosalicylate